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Anti-mitochondrial therapyDuring multi-cellular tumor spheroid growth, oxygen and nutrient gradients develop inducing speciﬁc genetic
and metabolic changes in the proliferative and quiescent cellular layers. An integral analysis of proteomics,
metabolomics, kinetomics and ﬂuxomics revealed that both proliferative- (PRL) and quiescent-enriched
(QS) cellular layers of mature breast tumor MCF-7 multi-cellular spheroids maintained similar glycolytic rates
(3–5 nmol/min/106 cells), correlating with similar GLUT1, GLUT3, PFK-1, and HKII contents, and HK and LDH
activities. Enhanced glycolytic ﬂuxes in both cell layer fractions also correlatedwith higherHIF-1α content, com-
pared to MCF-7 monolayer cultures. On the contrary, the contents of the mitochondrial proteins GA-K, ND1,
COXIV, PDH-E1α, 2-OGDH, SDH and F1-ATP synthase (20 times) and the oxidative phosphorylation (OxPhos)
ﬂux (2-times) were higher in PRL vs. QS. Enhanced mitochondrial metabolism in the PRL layers correlated
with an increase in the oncogenes h-Ras and c-Myc, and transcription factors p32 and PGC-1α, which are in-
volved in the OxPhos activation. On the other hand, the lower mitochondrial function in QS was associated
with an increase in Beclin, LC3B, Bnip3 and LAMP protein levels, indicating active mitophagy and lysosome bio-
synthesis processes. Although a substantial increase in glycolysis was developed, OxPhos was the predominant
ATP supplier in both QS and PRL layers. Therefore, targeted anti-mitochondrial therapy by using oligomycin
(IC50=11 nM), Casiopeina II-gly (IC50=40 nM) or Mitoves (IC50=7 nM) was effective to arrest MCF-7 spher-
oid growth without apparent effect on normal epithelial breast tissue at similar doses; canonical anti-neoplastic
drugs such as cisplatin and tamoxifen were signiﬁcantly less potent.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Accelerated glycolysis, even in the presence of saturated O2
concentration is a common characteristic of all studied neoplasias
[reviewed in 1,2]. However, the relevance of oxidative phosphoryla-
tion (OxPhos) supporting cancer growth has been documented for a
variety of cancer cell lines [1, reviewed in 3] and experimental
models, including bi-dimensional [3,4] and tri-dimensional systemsBnip 3, Bcl2/adenovirus EIB
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rights reserved.(also called human tumor multi-cellular spheroids – MCTS – which
resemble early stages of solid tumor) [5–7], and xenografts in mice
[8,9]. In this regard, it has been described that OxPhos supports the
high ATP demand required during the early stages of HeLa and
Hek293 MCTS growth [7]. However, the addition of mitochondrial in-
hibitors such as Casiopeina-IIgly (CasII-gly) only induces a partial
diminution of tumor spheroid growth, indicating that HeLa and
Hek293 MCTS proliferation may also be supported by glycolysis [7].
The metabolic reprogramming of mature MCTS (close to 1 mm di-
ameter) involves a marked increase in HIF-1α-activated glycolysis
and severe OxPhos depression [7]. The molecular mechanism associ-
ated with the glycolytic activation triggered by the development of a
hypoxic microenvironment in the tumor core, involves the HIF-1α
stabilization and enhancement in the glycolytic gene transcription,
protein contents, enzyme activities and ﬂux [reviewed in 10].
Solid tumors develop a tri-dimensional structure that favors the for-
mation of nutrients and oxygen gradients, which in turn promotes the
formation of three regions with clearly different phenotypes [11,12].
These three well-deﬁned regions (the proliferative, quiescent and the
necrotic center) have been analyzed as a whole, i.e., in mature, entire
MCTS (HeLa, Hek293, U343MG, EMT6/Ro, BT474, DU145, T47-D) in
which growth rate, morphology and physiology have been determined
[7,13–21]. However, the phenotypic characteristics determined in
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inside the tumor derived from the large metabolite and oxygen ﬂuctu-
ations throughout the spheroid [11,21].
Regarding energy metabolism, scarce information is available on
its cellular zonation across MCTSs. Freyer [16,22] described a severe
diminution in the rhodamine123 retention, and presumably oxygen
consumption, in both outer and inner cellular layers of EMT6 mouse
mammary carcinoma and 9L rat glioma MCTSs in comparison to
cells grown as monolayers [16,22]. Unfortunately, the rhodamine123
concentration used in these studies promotes severe perturbation to
the OxPhos by acting both as an uncoupler and an inhibitor of the
ATP/ADP translocator and ATP synthase [23,24], making difﬁcult the
interpretation of results. In addition, the cellular oxygen consumption
measurements in MCTSs have not usually been corrected by using a
respiratory chain inhibitor or oligomycin to discard the O2-uptake
by non-mitochondrial enzymes, whose activity is 2.5–5 times in-
creased in tri-dimensional models [25,26].
In solid tumors and probably in MCTS models, prolonged hypoxia
promotes a metabolic symbiosis in which the lactate overproduced by
the highly glycolytic and hypoxic cells (i.e., inner, and presumably,
quiescent cell layers) is actively consumed by the blood-closer and
well-oxygenated cells (i.e., external layers) for oxidative metabolism.
This metabolic switch involves the over-expression of, at least, two pro-
teins in the oxidative tumor cells, which are required for the massive
lactate uptake (MCT-1) and for the rapid cytosolic lactate oxidation
(LDH-B) to generate pyruvate, which in turn, enters into the mitochon-
dria for generation of reducing equivalents and ATP [27]. These obser-
vations strongly suggest that the micro-area, in which the tumor cell
lies inside MCTS, may modify the energy cellular metabolism. There-
fore, the identiﬁcation of the principal energy supply pathway for
each cellular population in the MCTSs, and solid tumors, and hence
the use of speciﬁc and potent metabolic inhibitors against this particu-
lar pathway may be considered as a potential anti-tumor strategy.
To analyze the bioenergetics of theMCTS external and inner cellular
layers, proteomic analysis, kinetic determinations and metabolic ﬂuxes
of OxPhos and glycolysis were performed in disaggregated mature
spheroids. In parallel, the expression patterns of several transcription
factors involved in the modulation of glycolysis and mitochondrial me-
tabolismwere also analyzed. Once the principal ATPproducerwas iden-
tiﬁed, speciﬁc anti-tumor therapy was designed for the entire mature
MCTS using permeable and selective inhibitors to diminish tumor
growth. In parallel, canonical chemotherapy drugs were evaluated on
MCTS growth for comparative purposes. Results of the present study
may contribute to the better understanding of the energy metabolism
changes in the basic unit of tumor growth and provide guidance in
the design of more appropriated targeted clinical treatment strategies.
2. Materials and methods
2.1. Monolayer and spheroid cultures
Breast human tumor stage-3 MCF-7 (1×107 cells/dish) and the
normal epithelial breast MCF-12A cells (American Type Culture
Collection; Rockville, MD, USA) were grown in Dulbecco-MEM medi-
um supplemented with 10% fetal bovine serum (GIBCO; Rockville,
MD, USA) plus 10,000 U penicillin/streptomycin (SIGMA; Steinheim,
Germany) and placed under a humidiﬁed atmosphere of 5% CO2/
95% air at 37 °C during 3–4 days until conﬂuence of 80–90% was
reached. The genotyping of the MCF-7 cells (National Institute of Ge-
nomic Medicine, Mexico) used in the present study revealed that they
are already a subclone because they only share 5 out of 14 canonic al-
lelic markers with the original MCF-7 clone (American Type Culture
Collection; Rockville, MD, USA). Afterwards, cells were gently de-
tached from the culture dish by a 2–3-min exposure to 3 mL of
0.25% trypsin/EDTA (GIBCO), followed by washing with fresh Krebs–
Ringer medium (125 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.4 mMCaCl2, 1 mM H2PO4, 25 mM HEPES, pH 7.4) and centrifugation at
300×g for 2–4 min at room temperature [28].
MCF-7 and MCF-12A spheroids were formed by using the liquid
overlay modiﬁed technique [29,30]. Brieﬂy, 1×105 cells were seeded
in 2% (w/v) agarose-coated Petri dishes. Once spheroids reached a di-
ameter of 100±57 (MCF-7; n=140) or 197±30 (MCF-12A; n=80)
μm, medium was replaced with fresh medium and placed under slow
(20–50 rpm) orbital shaking for additional 14–18 (MCF-7) or 9–10
(MCF-12A) days at 37 °C under 95% air/5% CO2. Fresh medium was
added every 2–3 days to remove cellular debris and non-well formed
spheroids. The size of breast tumor and non-tumor spheroids wasmea-
sured at different culture times with a graduated reticule (1/10 mm;
Zeiss, Thornwood, NY, USA) in an inverted phase contrast microscope
(Zeiss).
2.2. Selective disaggregation of MCF-7 spheroids
Mature spheroids (863±64 μm diameter after 20 days of culture;
n=140; Fig. 1A) were sequentially trypsinized using the standard
dissociation method [13] to separate both external (proliferative)
and internal (quiescent+apoptotic) cell populations. Brieﬂy, 20–40
spheroids were exposed to 5 mL 0.25% trypsin/EDTA under gentle or-
bital agitation (20–50 rpm) at 37 °C for 3 min. Then, two fractions
were collected: a supernatant containing proliferative cells and a bot-
tom constituted by the quiescent cells. Both cellular fractions were
gently washed with fresh medium and centrifuged at 34,000×g for
5 min, at 37 °C. The cellular bottoms were re-suspended in fresh
D-MEM and stored at room temperature until use. Cellular viability
was determined by using the blue trypan method [4], which yielded
values of 87±8 and >95±5% for quiescent (QS) and proliferative
(PRL) cell-enriched layers, respectively. Cellular protein was deter-
mined by using the Biuret assay as described elsewhere [4].
To determine the growth capacity of each isolated MCTS (QS or
PRL) fraction, the cells (5×104 cells) were seeded in 1 mL D-MEM
in 24 multi-well plates and incubated at 37 °C, under 5%CO2/95%
air. Cellular numbers were quantiﬁed every 48 h until 144 h of cul-
ture by using the trypan blue assay [4].
2.3. Immunohistochemical analyses of the MCTS
Mature spheroids were ﬁxed by incubating with 10% paraformalde-
hyde at 4 °C overnight and washed with fresh phosphate buffer. After-
wards, spheroids were embedded in parafﬁn and sectioned into 2 μm
thick layers. Cut layers were stained with the primary Ki-67 antibody
(Santa Cruz, CA, USA) at a ﬁnal dilution of 1:70 for 20 min or with he-
matoxylin & eosin (H&E). The Ki67 and H&E detection was performed
in the automated BenchMark ULTRA system (Roche, Tucson, AZ, USA)
using the ultraView Universal DAB detection system (Ventana Medical
System Inc, Tucson, AZ, USA) following established protocols [31].
2.4. Determination of metabolic ﬂuxes
ForOxPhosﬂux, oligomycin-sensitive respirationwas determined at
37 °C in both quiescent (3.5–4×106 cells) and proliferative (1–1.5×106
cells) cell fractions by using a Clark-type electrode in an air-saturated
Krebs–Ringer medium plus 5 mM glucose. To reveal the activity of
the respiratory chain, KCN-sensitive respiration was also determined.
For glycolysis, both outer (proliferating) and inner (quiescent) cell-
enriched layers (1–30×106 cells) were pre-incubated for 10 min in
3 mL Krebs–Ringer medium under orbital shaking (150 rpm, 37 °C)
and afterwards, 5 mM glucose was added. After 3 min, samples were
precipitated with 3% (v/v) ice-cold perchloric acid and neutralized
with 3 M KOH/0.1 M Tris. Neutralized samples were used for lactate,
ATP and ADP determinations [32]. L-Lactate generated by glycolysis
was determined by using lactate dehydrogenase following the NADH
formation at 340 nm [33].
Fig. 1. (A) MCF-7 spheroid growth and MCTS cell layer proliferative proﬁle. Diameters of at least 70 MCF-7 spheroids were determined from day 5 to day 20. At day 24 or 25, mas-
sive cellular disintegration was detected. Upper panel insert shows a micrography of the 5, 15 and 20–23 day (D) old MCF-7 MCTSs; bar represents 200 μm. (B) Proliferative (PRL)
and QS (quiescent) layers coming from disaggregated MCF-7 spheroids were cultured in monolayer as described under Materials and methods. *Pb0.05 vs. QS, n=3, for non-paired
two-tailed Student's t test and one way ANOVA. (C) Proteomic analysis of PRL and QS markers in MCF-7 QS and PRL cells. Bars represent the mean±SD of 75 spheroids. *Pb0.05 vs.
QS. (D) Representative immunohistochemistry images of 14 Ki67-stained (left panel; n=14) or 8 hematoxylin & eosin-stained (right panel; n=8) mature MCF-7 spheroids. Due to
the fragility of the samples no always manageable cuts from entire spheroids were attained.
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For cytochrome c oxidase (COX) determination, cells were incu-
bated in air-saturated KME (125 mM KCl, 20 mM MOPS and 1 mM
EGTA, pH 7.4) buffer plus 0.02% Triton X-100, 50 μM horse muscle
cytochrome c and 5 mM sodium ascorbate at 37 °C. The oxidation
of reduced cytochrome c was spectrophotometrically monitored at
550 minus 540 nm in a dual-beam UV-visible spectrophotometer
(2501PC, Shimadzu, Japan). The COX reaction was started by adding
1 mg cellular protein/mL. In parallel experiments, 20 mM sodium
azide or 1 mM KCN was added to speciﬁcally block COX activity
[34]. Succinate dehydrogenase (SDH) activity was assayed in SHE
(250 mM Sucrose, 10 mM HEPES and 1 mM EGTA, pH 7.3) buffer
plus 0.5 mg cellular protein/mL, 0.2 mM 2,6-dichloroindophenol
(DCPIP), 0.4 mM phenazine methosulfate (PMS), 0.02% Triton
X-100, 50 μM MgCl2 and 1 mM cyanide at 37 °C. The reaction was
started by adding 10 mM succinate and the rate of DCPIP reduction
was determined by measuring the absorbance change at 600 nm
using an extinction coefﬁcient of 21.3 mM−1 cm−1 [35].
For glycolytic enzyme activities, cellular extracts from both prolifer-
ating and quiescent cells (30×106 cells or 2 mg cellular protein/mL)
were suspended in 25 mM Tris–HCl buffer, pH 7.6 plus 1 mM EDTA,
5 mM DTT and 1 mM PMSF, and subjected to three cycles of freezing
in liquid N2 and thawing at 37 °C [36]. Hexokinase (HK) activity was
assayed in 50 mMMOPS buffer, pH 7.0 at 37 °C in the presence of 2 U
glucose-6-phosphate dehydrogenase (Roche; IN, USA), 1 mM NADP+,
15 mM MgCl2, 10 mM ATP and 20–60 μg cellular extract protein/mL.
The reaction was started by adding 3 mM glucose after 3 min of
pre-incubation and generation of NADPH was measured at 340 nm.
The activity of hexosephosphate-isomerase (HPI) was determined in
50 mMMOPS buffer, pH 7.0 at 37 °C plus 2 U glucose-6-phosphate de-
hydrogenase, 1 mM NADP+ and 10–20 μg cellular extract protein/mL.
The reaction was started by adding 2 mM fructose-6-phosphate.
Lactate dehydrogenase (LDH) was assayed in 50 mM MOPS, pH 7.0
at 37 °C, 0.15 mM NADH and 10–20 μg cellular extract protein/mL;
after 3 min pre-incubation, the reaction was started with 1 mM
pyruvate and NAD+ formation was registered at 340 nm. All enzy-
matic assays showed no reaction when the speciﬁc substrates were
omitted [36].2.6. Proteomic analysis
For Western blot, quiescent and proliferative cells were dissolved
in RIPA (PBS 1× pH 7.2, 1% IGEPAL NP40, SDS 25% and sodium
deoxycholate 0.05%) lysis buffer plus 5 mM of protease inhibitors
(Roche, Mannheim, Germany). Protein (40 μg) was re-suspended
again in loading buffer plus 5% β-mercaptoethanol and loaded onto
12.5% polyacrylamide gel under denaturalizing conditions [7]. Elec-
trophoretic transfer to PVDF membranes (BioRad; Hercules, CA,
USA) was followed by overnight immunoblotting with 1:1000 dilu-
tion of PCNA, p27Kip1, α-tubulin, GLUT-1, GLUT-3, HKII, LDH-A,
α-KGD, GA, ANT, ND1, COX-IV, PDH-E1α, SDHC, p32, p53, TIGAR,
PGC-1α, H-Ras, c-Myc, Atg7, Beclin, LC3B, and LAMP-1 antibodies;
or 1:200 dilution of PFK-1, GAPDH, ATP synthase, Bnip3 antibodies;
or 1:500 dilution of Ki-67 antibody; or 1: 5000 dilution of HIF-1α
antibody at 4 °C. All antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). The hybridization bands were re-
vealed with the corresponding secondary antibodies conjugated
with peroxidase (Santa Cruz). The signal was detected by chemilumi-
nescence using the ECL-Plus detection system (Amersham Biosci-
ence; Piscataway, NJ, USA). Densitometric analysis was performed
using the Scion Image Software (Scion Corp, Bethesda MD, USA)
and normalized against its respective load control. Percentage of
each isoform represents the mean±SD of at least three independent
experiments.2.7. Proteomic analysis of transcription factors and oncogenes in
bi-dimensional MCF-7 cultures under chronic hypoxia
MCF-7 monolayer cultures at 80–90% conﬂuence were placed in a
humidiﬁed hypoxia incubator chamber (Billups-Rothenberg; Del Mar,
California, USA) saturated with 95% N2/5% CO2 to give approximately
0.1% O2atmospheric at 2240 m altitude and further incubated at 37 °C
for 24 h. Afterwards, cells were collected and processed as described
in the Proteomic analysis section.
2.8. Half maximal inhibitory concentrations (IC50) for mitochondrial and
glycolytic inhibitors and for canonical anticancer-drugs on growth of
normal epithelial breast and tumor breast spheroids
Both MCF-7 and MCF-12A spheroids were cultured in DMEM and
in the presence of glycolysis (iodoacetate) or OxPhos (rhodamines
123 and 6G, Casiopeina II-gly, oligomycin, Mitoves) inhibitors or in
the presence of the canonical anti-tumor drugs tamoxifen or cisplatin.
Inhibitors were sterilized by ﬁltration and added at the beginning of
MCTS formation (day 5 for both spheroids, once the primary core
was formed). The DMEM medium plus the inhibitor was replaced
every three days. The IC50 values were determined at day 17 (MCF-7)
or at day 11 (MCF-12A). In a second set of experiments, the
drugs were added to mature tumor spheroids (at day 15 of culture,
diameter ≈500 μm) and the medium plus inhibitor was replaced
every three days. Mitoves, oligomycin, tamoxifen and cisplatin were
diluted in 70% ethanol/30%DMSO. The addition of vehicle did not mod-
ify the MCTS growth.
2.9. Statistical evaluation
Data are expressed as mean±SD of the indicated number of
independent experiments. Analysis was performed using non-paired
two-tailed Student's t test; P values less than 0.05 were considered
signiﬁcant.
3. Results
3.1. Cellular growth and speciﬁc markers of proliferative and quiescent
MCF-7 spheroid layers
In order to assess the proliferative capacity of each MCF-7 spher-
oid cell population, cellular growth as well as the expression of the
proteins p27 (a selective quiescence marker whose expression is
associated with the inhibition of cyclin E/A-cdk2 complex), and Ki67
and PCNA (selective proliferation markers whose expression is asso-
ciated with the activation of the cellular cycle) [37,38] were deter-
mined in both the outer proliferative (PRL) and inner quiescent
(QS) enriched cellular fractions. After 48 h incubation (Fig. 1B),
the cellular number of the PRL fraction was signiﬁcantly higher
(from 5×104 to 20±10×104 cells) than that attained by the QS frac-
tion (from 5×104 to 8±1×104 cells; Pb0.005). At the 24 and
48 h-point (Fig. 1B), the number of generations of the QS fraction
was signiﬁcantly lower (0.3±0.08 and 0.4±0.1 generations/24 h, re-
spectively) compared to that attained by the PRL fraction (0.9±0.1
and 1±0.07 generations/24 h); these last values were close to the
value calculated for the proliferation of MCF-7 cells in monolayer
(1±0.2 generations/24 h) [28]. Interestingly, after 48 h culture the
QS fraction proliferative capacity was similar to that determined for
the PRL layer (1.1±0.1 vs. 0.9±0.05 generations/24 h, respectively);
however, the ﬁnal cellular content after 144 h was signiﬁcantly lower
in the QS fraction than in the PRL fraction (insert Fig. 1B).
The higher proliferation rate of the PRL cell fractions correlated
with their PCNA (3.4-fold) and Ki67 (5-fold) higher contents, and
p27 lower content (4.5-fold) versus the QS cell fractions (Fig. 1C). As
a comparative model, MCF-7 monolayer cultures were also analyzed.
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were similar to those observed for monolayer culture cells (Fig. 1C),
which demonstrated the proliferative status of the spheroid PRL cell
layer. To further support the proliferative phenotype of the PRL cell
fraction, the Ki67 content was also analyzed by immunohistochemis-
try in the entire ﬁxed mature MCF-7 MCTS (Fig. 1D, left panel). Dark
spots in the periphery of the spheroid represent the high Ki-67 inten-
sity observed in PRL layer conﬁrming their proliferative phenotype.
On the other hand, clear spots were observed in the inner MCTS cell
layer indicating scarce Ki67 staining which conﬁrms their quiescent
phenotype. Hematoxylin & eosin stain in the MCF-7 entire mature
spheroid revealed high cellular viability in both QS and PRL layers
and the complete absence of a necrotic center (Fig. 1D, right panel).
Therefore, the whole set of results shown in Fig. 1 clearly shows the
presence of two viable cell populations in mature MCTS with different
proliferative capacities.
3.2. Proteomic, kinetomic and ﬂuxomic analyses of glycolysis and OxPhos
in the MCF-7 MCTS proliferative and quiescent cells
High glycolytic capacity coupled to an enhanced HIF-1α level is an
important metabolic characteristic of solid tumors [39–41]. In bothFig. 2. Proteomic analysis of (A) HIF-1α and glycolytic proteins in MCF-7 monolayer (M), M
spheroids. *P≤0.05 vs. QS. (B) Mitochondrial proteins in MCF-7 monolayer (M), MCF-7 MC
oids. *P≤0.05 vs. QS.MCTS quiescent and proliferative enriched cell fractions, HIF-1α pro-
tein was signiﬁcantly higher (1.8–3.1-times) in comparison with
normoxic monolayer cultures (Fig. 2A). In consequence, as most of
the glycolytic proteins are up-regulated by HIF-1α [10], an increased
glycolytic ﬂux was determined for both cell layers (Table 1), which
was higher compared to that found in MCF-7 monolayer cultures, rat
hepatocytes, and tumor normoxic bi-dimensional cultures
(MDA-MB-453, HeLa, Hek293) and even in tumor cells exposed to
prolonged hypoxia in monolayer cultures [28,36,42].
Increased glycolytic ﬂux in both MCTS QS and PRL cells correlated
with high contents (245–544% vs. tubulin) and activities of ﬂux-
controlling (HK, GLUT1) and non-controlling (HPI, LDH) glycolytic
enzymes and transporters [36] (Fig. 2A, Table 1). This high expres-
sion pattern was not observed for other glycolytic proteins such as
GLUT3, PFK-1 and GAPDH. The contents of GLUT1, HKII and LDH-A
in both MCTS cell fractions were also signiﬁcantly higher than
those found in normoxic MCF-7 monolayer cultures (Fig. 2A). On
the other hand, the activities of HK and LDH (Table 1) in both QS
and PRL fractions were higher than those reported for normal tissue
[43–45] and within the same range determined for bi-dimensional
MCF-7 cultures (10±6, n=3 and 100, n=2 mU/mg protein, respec-
tively) and entire MCTSs [28].CF-7 MCTS quiescent (QS) and proliferative (PRL) cells. Data represent mean±SD of 50
TS quiescent (QS) and proliferative (PRL) cells. Data represent mean±SD of 50 spher-
Table 1
OxPhos and glycolysis in monolayer MCF-7, quiescent (QS) and proliferative (PRL) MCF-7 MCTS cellular populations.
Monolayer % ATP produced QS % ATP produced PRL % ATP produced
Total respiration 9.4 (2) 62±20 (7)* 113±28 (6)
OxPhos 6.7 (2) 92 25±10 (7)* 93 53±18 (6) 98
SDH 3.3±1.2 (4)* 2.3±1.3 (4)* 5.2±1.9 (4)
COX ND 1±1 (4) 3±2 (4)
Glycolysis 1.4±0.8 (4)* 8 4.5±2 (3) 7 3.1±1.6 (3) 2
HK 7.7±4.6 (3) 11±8 (5) 14±4 (4)
HPI 736±228 (3) 579±282 (5) 669±333 (4)
LDH 100 (2) 393±133 (5) 566±330 (5)
ATP 9.2±2.3 (3) 8±1 (3) 9±3 (3)
ADP 1.6±0.4 (3) 1.3±0.5 (3) 2.1±0.5 (3)
Fluxes are expressed in ngAO/min/106 cells for OxPhos and in nmol/min/106 cells for glycolysis. KCN-sensitive respiration was 52±24% and 73±11% of total respiration (n=4) for
QS and PRL cells, respectively. Activities are expressed in mU/106 cells. Nucleotides are expressed in nmol/106 cells. OxPhos ATP-contribution was calculated assuming a P/O ratio of
2.5 [88], whereas for glycolysis, 1 ATP=1 lactate. Data represents mean±SD. (n) represents the number of different spheroid preparations analyzed. *Pb0.05 vs. PRL. Abbrevia-
tions: COX, cytochrome c oxidase; HK, hexokinase; HPI, hexose-phosphate isomerase; LDH, lactate dehydrogenase; SDH, succinate dehydrogenase. The viability of the cells was
>85% for both PRL and QS layers.
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higher total oxygen consumption and oligomycin-sensitive respiration
(OxPhos) than cells derived from the MCTS quiescent layer (Table 1).
In turn, both QS and PRL layers OxPhos ﬂuxes were 3–7 times higher
than that determined for the normoxic MCF-7 monolayer cells
(Table 1) and for the entire MCTS [7,28]. Increased total cellular
respiration and OxPhos in proliferative cells correlated with a signiﬁ-
cant elevation in the contents of the mitochondrial enzymes 2-OGDH
(34-times), PDH-E1α subunit (4.4-fold), glutaminase-K (3-times),
respiratory chain NADH dehydrogenase complex 1 (3.1-fold) and cyto-
chrome c oxidase complex IV (2-times); and ATP synthase subunit 5
(6-times) (Fig. 2B), compared to QS cells. Activities of COX and SDH
(3-times) also increased inMCTS proliferative cell layer vs.MCTS quies-
cent cells (Table 1). The protein contents of ND1 and ANT found in the
PRL layers were similar to those observed in normoxic monolayer cul-
tures; however, the contents of other mitochondrial proteins such as
2-OGDH, GA-K, PDH-E1α and ATP synthase were signiﬁcantly higher,
or lower (SDH), in PRL compared to bi-dimensional cultures (Fig. 2B).
Although high glycolytic rates were determined in both MCTS
proliferative and quiescent cell layers, contribution to ATP supply by
glycolysis was less than 10%, indicating that MCTS, like MCF-7 mono-
layer cells (Table 1), strongly depend on OxPhos [28]. On the other
hand, steady state ATP and ADP concentrations, as well as the ATP/ADP
ratio were similar in both MCTS quiescent and proliferative cells as
well as MCF-7 bi-dimensional culture (Table 1) [28].3.3. Expression of autophagic proteins and transcription factors
associated with changes in mitochondrial metabolism in quiescent and
proliferative layers
In an initial attempt to determine the mechanisms associated with
the high OxPhos ﬂux and mitochondrial protein contents in the PRL
cells, the pattern of transcription factors involved in the regulation
of tumor mitochondrial metabolism [46,47] was evaluated in both
MCTS cellular fractions and compared to monolayer cells exposed to
normoxic and hypoxic conditions (Fig. 3A). In the PRL layers where
OxPhos predominates for ATP-supply (Table 1), the main transcrip-
tion factors involved in the de novo synthesis of respiratory chain
components (p32 and h-Ras), β-oxidation (PGC-1α) [reviewed in
48] and mitochondrial biogenesis (c-Myc) [46,47,49] signiﬁcantly in-
creased (53–73%) versus the quiescent cell layers (Fig. 3A). The pro-
tein contents of p32, p53, c-Myc and h-Ras in the PRL layers were
similar to those found in normoxic-MCF7 monolayer cells, whereas
the PGC-1α level was remarkably higher in the PRL layers. On the
other hand, p32 and h-Ras levels found in QS layers were signiﬁcantly
lower to those observed in hypoxic MCF-7 monolayer cells, suggestingthat hypoxia is not the only factor that modulates expression of these
transcription factors inside the tumor spheroids (Fig. 3A).
Interestingly, diminution in OxPhos ﬂux, and COX and SDH activ-
ities in QS cells (Fig. 2B, Table 1) correlated with high contents of p53
(Fig. 3A) and autophagy proteins (Beclin, LC3B, Bnip3 and LAMP)
compared with PRL cells, indicating mitophagy activation (Fig. 3B).
TIGAR, a glycolytic tumor modulator was expressed at similar levels
in both MCTS layers correlating with similar glycolytic enzyme activ-
ities, transporter and enzyme contents, and ﬂux rates (Table 1).
As the oxygen concentration in the inner QS layers of mature MCTS
is low (7–14 μM O2, [11]), and to make a stricter comparison, the
contents of the mitophagy proteins were also analyzed in MCF-7
monolayer cultures exposed to prolonged and chronic hypoxia
(24 h, 13 μM O2 [28]). The levels of p53, TIGAR, and autophagy pro-
teins, except for Atg7, in the QS layers were similar to the protein pro-
ﬁles determined in the MCF-7 monolayer model exposed to chronic
hypoxia (Fig. 3B).
3.4. Sensitivity of MCTS growth to energy metabolism inhibitors and
canonical anticancer drugs
The results shown in the previous sections clearly demonstrated
that the well-formed QS and PRL cellular layers constituting the en-
tire MCF-7 spheroid depend on OxPhos for ATP supply (Table 1).
This ﬁnding may presumably also be applied to the growth of solid
tumors. Therefore, the addition of typical mitochondrial inhibitors
but not glycolytic inhibitors should induce a severe arrest of the
MCF-7 MCTS growth. To assess this hypothesis, MCF-7 spheroids
were cultured in the presence of oligomycin (a speciﬁc mitochondrial
ATP synthase inhibitor) or iodoacetate (IAA, a GAPDH inhibitor) [50;
reviewed by 51] (Fig. 4A). Oligomycin abolished the growth of MCF-7
at remarkably low concentrations whereas no apparent effect was
achieved by IAA (Table 2). However, oligomycin is also extremely
toxic for normal, healthy cells [52,53].
Then, rhodamines 123 (rhod123) and 6G (rhod6G), Casiopeina
II-gly (CasII-gly) andMitoves (MV11), lipophilic cationic drugswith po-
tent inhibitory effect on mitochondrial metabolism, and the canonical
anticancer drugs tamoxifen and cisplatin [reviewed by 51, 54] were
also evaluated for their effects onMCTS growth (Fig. 4A). For a rigorous
comparative analysis, CasII-gly, MV11 and cisplatin (CP) were also
assayed in non-tumor but highly proliferative normal breast cell line
MCF-12A. CasII-gly and MV11 severely abolished the growth of MCTSs
at therapeutically relevant low doses (Table 2) whereas rhodamines
123 and 6G were less effective. Compared to the canonical chemother-
apy drugs tamoxifen (Tam) and CP, CasII-gly and MV11 showed higher
potency against MCTS cells. Remarkably, these energy metabolism
drugs were approximately one order of magnitude more selective for
Fig. 3. Proteomic analyses of (A) transcription factors and (B) mitophagy proteins involved in the regulation of the mitochondrial function in QS and PRL cells fromMCF-7MCTSs. As
a control, the proteomic analysis was also carried out with monolayer MCF-7 cells exposed to normoxic (N, 21% O2) or hypoxic (H, 0.1% O2) conditions for 24 h. Data represent
mean±SD of 50 spheroids. *P≤0.05 vs. QS.
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tencies for both types of spheroids (Table 2, Fig. 4B).
Well-formed MCTSs of 500 μm diameter (day 15) were also ex-
posed to CasII-gly, MV11 or CP. After three days, MV11 completely
arrested growth, whereas Cas-IIgly and CP were relatively innocuous
(Fig. 5A). However, six days later (day 21), CasII-gly and CP also
abolished growth and induced cell death (Table 2, Fig. 5B).
4. Discussion
Bi-dimensional cultures of cancer cells have been profusely
employed as a model for analyses of their radio- and chemotherapy
response, intermediary metabolism, bioenergetics studies, and signal-
ing [36,55,56] among others, providing useful information for under-
standing tumor physiology. However, the monolayer cultured tumor
cells do not strictly reﬂect the behavior of solid tumors regarding
the spatial organization. Three-dimensional multi-cellular tumor
spheroids (MCTSs) better resemble the heterogeneous microenviron-
ment found in solid tumors, in which physiological and biochemical
differences throughout the cellular layers are generated [57]. There-
fore, strategies directed to slow-down the accelerated tumor cell
proliferation should take these spatial-driven changes into accountto be able to improve treatment protocols. In the present study we
characterized the predominant energy metabolism in each cellular
layer derived from an early-stage solid tumor model to propose
alternative therapies for cancer treatment improvement.
4.1. Enhanced OxPhos in MCTS proliferative-enriched cell fractions, and
depressed OxPhos in quiescent-enriched cell fractions
After disaggregation of mature MCTSs, the two separated cellular
layers showed different proliferation proﬁles (cf. Fig. 1), indicating
that indeed, QS and PRL-enriched cell fractions contain distinctive
cellular subpopulations with contrasting metabolic changes. In terms
of energy metabolism, glycolysis and OxPhos have been analyzed in
whole MCTSs (HeLa, Hek-293, transformed rat embryo ﬁbroblasts,
BMG-1, HepG2) where glycolytic metabolism seems to be the principal
cellular ATP supply [7,58–60]. However, prolonged anti-glycolytic treat-
ments in the entire MCTSs do not block tumor proliferation, suggesting
that OxPhos has also a signiﬁcant role in sustaining cellular growth
[7,59].
No information is yet available regarding analysis of both OxPhos
and glycolysis in dissected tumor spheroids. The majority of the stud-
ies with MCTSs have focused on the role of the mitochondrial
Fig. 4. Effect of oxidative and glycolytic inhibitors, and canonic chemotherapy drugs
on MCF-7 (A) and MCF12A (B) spheroid growth. Spheroids were grown as described
under Materials and methods. All inhibitors or drugs used were added at the beginning
of the spheroid formation (day 5). Spheroid growth values were normalized vs.
non-inhibited growth at day 17 (MCF-7 MCTS diameter ≈760 nm) or at day 11
(MCF12A spheroid diameter ≈360 nm). Abbreviations: CasII-gly, Casiopeina II-gly;
CP, cisplatin; IAA, iodoacetate; MV11, Mitoves; Tam, tamoxifen, Oligo, oligomycin.
Data shown represent the mean±SD of 3 independent preparations except for
MCF12 A+Cas-IIgly (n=2).
Table 2
IC50 (nM) values of metabolic and canonical anticancer drugs in non-tumor and tumor
spheroids.
Drugs MCF-7 spheroids MCF12A spheroids
Initial cluster Well-formed Initial cluster
Anti-mitochondrial
MV11 7±1.6 (3) 9.7±3 (3) 96±14 (3)
CasII-gly 40±14 (3) 28 (2) 360 (2)
Rhod123 >500 (3)
Rhod 6G 79±18 (3)
Oligo 11±4 (3)
Anti-glycolytic
IAA >500 (3)
Canonical
Tam >500 (3)
CP 76±1.3 (3) 55±5 (3) 54±20 (3)
The indicated drugs were added at the beginning of the spheroid formation (day 5
for both spheroids, initial cluster) and the IC50 values were determined at day 17
(MCF-7, diameter≈760 μm), or at day 11 for non-tumor spheroids (MCF-12A, diam-
eter ≈360 μm). The drugs were also added to well-formed tumor spheroids (at day
15 of culture, diameter ≈500 μm).
Fig. 5. Effect of Cas-IIgly, MV11 and CP onmature MCF-7 MCTS. All drugs were added at
day 15 once MCTSs reached around 500 μM of diameter. MCF-7 MCTSs were recollect-
ed at day 18 (A) or day 21(B) after drug addition. Abbreviations are as in Fig. 4. Data
shown represent the mean±SD of 3 independent experiments except for Cas-IIgly
(n=2).
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mitochondrial density and total oxygen consumption are similar
across the rim of human melanoma MCTSs [61]. However, total cellu-
lar respiration does not accurately reﬂect mitochondrial ATP synthe-
sis because high activities of non-mitochondrial O2-consumption
enzymes (hemo oxygenases, cytochrome p450 and NADPH oxidase)
are also developed in tumor spheroid models [25,26]. Therefore,
oligomycin- and cyanide-sensitive cellular respiration should be eval-
uated for precise determinations of OxPhos and maximal respiratory
chain capacity, respectively. For instance, cyanide-sensitive cell respi-
rations of the MCTS PRL and QS layers were 73 and 52%, respectively,
of the total cell respirations (see values in the legend to Table 1), in-
dicating signiﬁcant O2 consumption by non-mitochondrial processes
and perhaps production of radical oxygen species by the respiratory
chain.
Nonetheless, in dissected rodent EMT6 and 9L MCTSs a severe
diminution (60%) in total oxygen consumption on quiescent vs. ex-
ternal cellular fraction has been described [16,22], which is of a
very similar extent (61%) to that determined in the present study
for cyanide-sensitive respiration in MCF-7 MCTS QS cell layers versus
PRL layers (Table 1). Moreover, in EMT6 and 9L MCTS cellular
populations located close to hypoxic and hypoglucemic areas, a dras-
tic mitochondrial protein down-regulation (1–9 times, except for
ANT) has also been reported, which was also observed for the con-
tents of mitochondrial proteins of MCF-7 MCTS QS layers (except
for SDH and ANT; Fig. 2B) and HeLa cells cultured in monolayers
under severe and prolonged hypoxia (0.1% O2 for 24 h) [28].
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times higher than their monolayer (cf. Table 1) counterparts and than
other bi-dimensional cultured tumor cells (HepG2), which indicates
that the spheroid tri-dimensional arrangement (i.e., metabolite gradi-
ents and differential transcription factors and oncogene expression
proﬁles) somehow favors oxidativemetabolism independently of nutri-
ent and O2 supply [58]. Cyanide-sensitive and oligomycin-insensitive
respiration was also higher (11–29% of total respiration) in both
MCF-7 MCTS cell layers than that reported for MCF-7 monolayers
(10–15% of total respiration), suggesting an increased passive H+ diffu-
sion across the inner mitochondrial membrane probably derived from
higher contents of uncoupling proteins as described for human colon
adenocarcinoma [25,26,62].
4.2. Similar glycolytic metabolism in quiescent- and
proliferative-enriched MCF-7 MCTS layers
The hypoxic microenvironment generated in the center of mature
MCTSs formed from MCF-7 and other tumor cell lines [51,63] or the
exposure of tumor cell monolayers to severe and prolonged hypoxia
[28] induces the up-regulation of glycolytic enzymes, activities and
ﬂuxes. Stabilization of HIF-1α is involved in the solid tumor adapta-
tion to the hypoxic microenvironment (Figs. 2A, 3A) [64,65, reviewed
in 10], particularly of the QS cell fraction (Fig. 1B).
However, in the MCTS PRL-enriched cell fraction, where O2 avail-
ability is high, HIF-1α stabilization is also observed as well as the
signiﬁcant increase (4–5 times) in HIF-1α glycolytic target gene ex-
pression, enzyme activities (especially HK, one of the main control-
ling sites of tumor glycolysis [36]), and pathway ﬂux (Fig. 2A,
Table 1), compared with MCF-7 monolayer cells [28]. Similar results
have also been described for tumor spheroids from human glioma
BMG-1 and transformed rat embryo ﬁbroblast Rat1-T1, in which glycol-
ysis increased 1.5–2.5 times versus monolayer counterparts [60,66].
Thus, the present results with the MCTS PRL cell layers suggest that
HIF-1α stabilization may also be triggered by (i) accumulation of rele-
vant metabolites such as pyruvate/lactate and succinate/fumarate,
which compete with the prolyl hydroxylases substrate 2-OG, thus
avoiding HIF-1α degradation; and/or (ii) activation through p53,
h-Ras or PTEN oncogenes [67, reviewed in 10] as observed in prostate
tumor cells [68].
4.3. Underlying mechanism of OxPhos enhancement in MCF-7 MCTS
enriched proliferative cellular populations
Recently, it has been demonstrated that numerous transcription
factors such as p32, h-Ras, c-Myc, and PGC-1α positively modulate
OxPhos in well-oxygenated areas. p32 and h-Ras participate in the acti-
vation of the novo synthesis of tumor respiratory chain components
such as respiratory complex I, cytochrome c oxidase, ATP synthase
and pyruvate dehydrogenase [46,47], whereas PGC-1α is associated
with the activation of the free fatty acid mitochondrial β-oxidation
[reviewed in 48]. Also, PGC-1α and c-Myc have been associated with
activation of mitochondrial biogenesis under normoxic conditions [69,
reviewed in 48] and glutaminase-K expression in tumor cells (pancreat-
ic cancer PANC-1 andMIA PaCa-2, breast cancerMDA-MB-453) that are
close to blood vessel regions [69].
In the PRL cell fraction which is exposed to high oxygen concentra-
tions [28], all these transcription factors were found 2–9 times increased
compared to the QS-enriched cell fraction (Fig. 3A), therefore indicating a
more activemitochondrialmetabolism that correlatedwith increased (3–
7 times) levels of the ATP synthase, COX-IV, PDH-E1α and complex I
subunit 1, and OxPhos ﬂux (2-times). The high contents of c-Myc, h-Ras
and p32 found in the PRL layer were similar to those found in
bi-dimensional cultured under normoxic conditions (Fig. 3A), indicating
that factors different from hypoxia and the tri-dimensional architecture
may induce their cellular synthesis and stabilization. On the contrary,the levels of p32 and h-Ras in the QS fraction were lower than those
determined in MCF-7 cultured in monolayer under hypoxic conditions;
whereas PGC-1α was not detected in normoxic monolayer cells,
suggesting that the tri-dimensional arraymay favor their de novo synthe-
sis and stabilization.
Several mechanisms have been proposed to explain the low mito-
chondrial functionality in tumor quiescent cells. Freyer [16,22] pro-
posed that the decrease in mitochondrial oxidative metabolism was
associated with a signiﬁcant diminution in the actin content and
consequently low cellular volume, as occurs in prostate MCTS [70].
Another mechanism could be the increase in reactive oxygen species.
In this regard, it has been shown a signiﬁcant ROS accumulation in
the inner layers of mature glioma spheroids [reviewed in 71] which
affects mitochondrial functionality through mitophagy activation.
In hepatocellular tumor cells, moderate hypoxia (8 h, 1% O2) acti-
vates organelle degradation (peroxisomes, endoplasmic reticulum,
ribosomes and principally mitochondria) as a survival mechanism
maintaining nutrient supply [72,73]. In order to determine whether
mitophagy activation [74,75] was involved in the observed lower
mitochondrial function in the QS layers, a panel of essential mitophagy
proteins was determined in the MCTS cell fractions. Elevated contents
(3–5 times) of Atg7 (required for peroxisomal and vacuolarmembranes
fusion), Beclin (required for autophagy onset and autophagosome
formation), LAMP (required for lysosome biogenesis) and Bnip3
(potent autophagy inducer) were detected in the QS fraction versus
PRL fraction, suggesting thatMCTSQS cellswere actively engaged inmi-
tochondrial degradation by lysosomal digestion (Fig. 3B). Except for
Atg7, the contents of the mitophagy proteins were similar between
MCTS QS layers and hypoxic monolayer cells (cf. Fig. 3B) indicating
that indeed, hypoxia could be the main inducer of mitophagy protein
synthesis.
The present study clearly demonstrates that both dissociated PRL
and QS layers maintain high dependency on OxPhos (cf. Table 1),
which contrasts with the entire and mature tumor spheroids where
the cellular ATP required for tumor growth is principally supplied
by glycolysis [7]. In the entire spheroids, three tumor microregions
(proliferative, quiescent and necro-apoptotic areas) co-exist provid-
ing their well-deﬁned 3D structure [11]. Specially, the apoptotic
area concentrates, and very likely produces high lactate content
[65], which may contribute to the high glycolysis rate found in the
entire spheroids. After spheroid dissociation (cf. Table 1, Fig. 2) the
apoptotic area is totally removed, the extra-lactate is eliminated and
in consequence, no over-estimated lactate production is attained for
the QS cell layers.
4.4. Anti-mitochondrial therapy as a potential anticancer strategy against
breast cancer
The identiﬁcation of OxPhos as the main pathway for ATP supply in
each tri-dimensional tumor cellular layer provides the rational basis for
the use of mitochondrial inhibitors to selectively arrest tumor prolifer-
ation. Indeed, the speciﬁc ATP synthase inhibitor oligomycin, as well
as the energy metabolism inhibitors CasII-gly [reviewed in 51] and
Mitoves [54] but not rhodamines 123 or 6G, potently and selectively
inhibited the growth of breast tumor MCF-7 MCTSs (Fig. 4A) and
induced cell death in well-formed MCTSs (Fig. 5) [51]. Rhodamines
123 and 6G as well as Cas-IIgly and Mitoves are lipophilic cations
which are expected to accumulate into functional mitochondria in a
process driven by the H+ electrochemical gradient (inside negative)
generated by the respiratory chain [reviewed in 51]. However, the
lower rhodamine potency to abolish tumor growth suggests that the
positive charge and the lipophilic nature targeting mitochondria do
not sufﬁce to efﬁciently stop cancer cell growth. Cas-IIgy and Mitoves
have additional features for their speciﬁc OxPhos targeting: Cas-IIgly
is also a SH-group reagent that more speciﬁcally targets 2-OGDH, PDH
and SDH [reviewed in 51];Mitoves acts as an uncoupler and also targets
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augment their antitumor potency.
Interestingly, the same doses of either anti-mitochondrial drug did
not affect the growth of non-tumor cells (Fig. 4B) suggesting that
OxPhos and mitochondria targeted by highly selective drugs such as
Cas IIgly or MV11 may be an effective therapeutic strategy against
breast cancer. Moreover, the anticancer activity of the mitochondrial
inhibitors, when added either at the beginning of the MCTS growth
or during growth of well-formed MCTS indicates that these drugs
may prevent and revert tumor cell proliferation.
Platinum-based chemotherapy (CP) and the positive estrogen re-
ceptor (ER+) blockers (tamoxifen, Tam) are routinely used in the
clinical treatment of early stage and positive ER breast cancer [76,77].
However, growth of MCF-7 MCTS, which represents an ER positive
breast carcinoma [78] was only slightly affected by Tam at 100 nM
(Figs. 4A and 5). In fact, it has been demonstrated that micromolar
doses of Tam are required to block MCF-7 cellular cycle and other
processes associated with tumor apoptosis onset [79,80]. However,
Tam micromolar doses may prompt unspeciﬁc side-effects affecting
non-tumor cells in the host such as erythrocytes [81]. Growth of
MCF-7 MCTSs was also highly sensitive to CP. Platinum-based drugs
destabilize DNA forming adducts, although at doses at which tumor
growth is arrested, these drugs also diminish respiratory chain com-
plexes I, III and IV activities and induce collapse of the mitochondrial
membrane potential [reviewed in 51,82,83]. Then, unspeciﬁc effects of
CP are expected on non-tumor cells as shown here for non-tumor
MCTS growth (Fig. 4B).
5. Concluding remarks
The analysis of the bioenergetics of the two cellular populations
constituting MCTSs, a solid tumor-like model revealed that (i) OxPhos
was the predominant pathway for energy supply in both PRL and QS
cells and (ii) there appears to be an interrelationship between onco-
genes (h-Ras, c-Myc) and tumor transcription factors (p32, PGC-1α)
with the contents of autophagy and mitochondrial energy metabolism
proteins. These observations suggest that using anti-mitochondrial
drugs (i.e., lipophilic cations) such as rhodamines, vitamin E analogs,
and copper-based compounds [reviewed in 84] to develop alternative
cancer treatment therapies may become promising strategies against
fast-growing breast tumors. This proposal was supported by the ob-
served potent and selective effect of these drugs on MCTS growth. Fur-
thermore, as glycolysis is involved in the ATP supply as well as in the
supply of essential metabolites required for biosynthetic pathways
(nucleotides, triacylglycerides and phospholipids, and some amino
acids), a multiple site therapy against energy metabolism (epitomized
by Cas-IIgly, which blocks both OxPhos and glycolysis) [85] emerges
as a suitable alternative strategy to efﬁciently arrest solid tumor growth
[86,87].
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